Amgen Inc.

Todd J Kohn

Sean P Brown

Jonathan B Houze

Paul John Dransfield

Marc Vimolratana

Julio Cesar Medina

Vatee Pattaropong

Wang Shen

Zice Fu

Jiwen Liu

Matthew R Kaller

Liusheng Zhu

Ana Elena Minatti

Brian Alan Lanman

Ming Yu

Michael G Johnson

Alexander J Pickrell

Jonathan Dante Low

Felix Gonzalez Lopez De Turiso

Paul E Harrington

Markian Myroslaw Stec

Timothy David Cushing

Zhihua Ma

Yi Heng Chen

Xiaohui Du

Patricia Lopez

Matthew Irvine Brown

Qingyian Liu

Shon Booker

Liping H Pettus

Rajiv Sharma

Jian Luo

Xuelei Yan

Albert Kudzovi Amegadzie

Nuria A Tamayo

Yosup Rew

Hui-Ling Wang

Xianghong Wang

Matthew Paul Bourbeau

Kexue Li

Yingcai Wang

Yunxiao Li

Joshua Taygerly

Michael J Schmitt

Xian Yun Jiao

Kate Ashton

SuJen Lai

Hilary Plake Beck

Zhongyu Wang

Jinqian Liu

XianYun Jiao

Michael W Gribble, Jr

David Karl Bedke

Jillian L Simard

Youngsook Shin

Alan C Cheng

Mario G Cardozo

Xiao He

Jason A Duquette

Ana Zurisadai Gonzalez Buenrostro

Zhihong Li

Gayathri Swaminath

An-Rong Li

Mike Elias Lizarzaburu

Jie Zhang

Michael R Degraffenreid

Jiasheng Fu

YuMei Xiong

Jennifer L Seganish

John R Butler

Julia Winslow Lohman

Manuel Zancanella

Yongli Su

Jiang Zhu

Margrit Schwarz

Yong-Jae Kim

Jeffrey D Reagan

Qiong Cao

Li Yang

Nicholas Anthony Weires

Daniel Lin

Diane Jennifer Beylkin

Primali Vasundera Navaratne

Rene Rahimoff

Mikkel Vestergaard

Sanne Omholt Schroder Glad

Francesco Manoni

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibits MCL-1 protein

Compounds that inhibit Mcl-1 protein

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110&#x3b4; activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Quinoline derivitives and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Heterocyclic compounds and their uses

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Substituted biphenyl GPR40 modulators

Heterocyclic GPR40 modulators

Growing community of inventors

Thousand Oaks, CA, United States of America

Todd J Kohn